{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:39Z","timestamp":1793103339088,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LabCorp"},{"name":"Enanta"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10620-020-06588-6","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T08:05:27Z","timestamp":1599465927000},"page":"3186-3191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare"],"prefix":"10.1007","volume":"66","author":[{"given":"Gabrielle","family":"Ritaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Stoleru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Sakiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-4740","authenticated-orcid":false,"given":"Uni","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"6588_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s10620-016-4085-6","volume":"61","author":"HL Reeves","year":"2016","unstructured":"Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 2016;61:1234\u20131245.","journal-title":"Dig Dis Sci"},{"key":"6588_CR2","first-page":"87","volume":"4","author":"C Thomas","year":"1873","unstructured":"Thomas C. Ulceration of the colon with a much enlarged fatty liver. Trans Pathol Soc Philos. 1873;4:87\u201388.","journal-title":"Trans Pathol Soc Philos"},{"key":"6588_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/00365529850166275","volume":"33","author":"G Riegler","year":"1998","unstructured":"Riegler G, D\u2019Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol. 1998;33:93\u201398.","journal-title":"Scand J Gastroenterol"},{"key":"6588_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/BF02591669","volume":"21","author":"C de Fazio","year":"1992","unstructured":"de Fazio C, Torgano G, de Franchis R, et al. Detection of liver involvement in inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res. 1992;21:314\u2013317.","journal-title":"Int J Clin Lab Res"},{"key":"6588_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00004836-200305000-00012","volume":"36","author":"S Bargiggia","year":"2003","unstructured":"Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417\u2013420.","journal-title":"J Clin Gastroenterol"},{"key":"6588_CR6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ibd\/izz043","volume":"25","author":"ZY Zou","year":"2019","unstructured":"Zou ZY, Shen B, Fan JG. Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1764\u20131772.","journal-title":"Inflamm Bowel Dis"},{"key":"6588_CR7","doi-asserted-by":"publisher","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","volume":"12","author":"MH Le","year":"2017","unstructured":"Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499.","journal-title":"PLoS One"},{"key":"6588_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/MIB.0b013e31827f27ae","volume":"19","author":"M Bewtra","year":"2013","unstructured":"Bewtra M, Kaiser LM, Tenhave T, et al. Crohn\u2019s disease and ulcerative colitis are associated with elevated standardized mortality ratios. Inflamm Bowel Dis. 2013;19:599\u2013613.","journal-title":"Inflamm Bowel Dis"},{"key":"6588_CR9","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s10620-017-4745-1","volume":"62","author":"L Haas","year":"2017","unstructured":"Haas L, Chevalier R, Major BT, et al. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62:3110\u20133116.","journal-title":"Dig Dis Sci"},{"key":"6588_CR10","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/ijms19082199","volume":"19","author":"LR Lopetuso","year":"2018","unstructured":"Lopetuso LR, Mocci G, Marzo M, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver. Int J Mol Sci. 2018;19:2199.","journal-title":"Int J Mol Sci"},{"key":"6588_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","volume":"30","author":"K Lapumnuaypol","year":"2018","unstructured":"Lapumnuaypol K, Kanjanahattakij N, Pisarcik D, et al. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2018;30:854\u2013860.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"6588_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","volume":"45","author":"RM Carr","year":"2016","unstructured":"Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016;45:639\u2013652.","journal-title":"Gastroenterol Clin North Am"},{"key":"6588_CR13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10620-017-4495-0","volume":"62","author":"RM Carr","year":"2017","unstructured":"Carr RM, Patel A, Bownik H, et al. Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci. 2017;62:1354\u20131361.","journal-title":"Dig Dis Sci"},{"key":"6588_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45: 846\u2013854.","journal-title":"Hepatology"},{"key":"6588_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/hep.30782","volume":"70","author":"ME Rinella","year":"2019","unstructured":"Rinella ME, Tacke F, Sanyal AJ, Anstee QM, participants of the AASLD\/EASL Workshop. Report on the AASLD\/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424\u20131436.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06588-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:50:57Z","timestamp":1630972257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06588-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6588"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06588-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was deemed by the Institutional Review Board at University of Maryland as Non-human Subjects Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}